Dr Vojo Vukovic joins Synta
This article was originally published in Scrip
Synta Pharmaceuticals, a US biopharmaceutical company focused on discovering, developing and commercialising small-molecule drugs to treat severe medical conditions, has appointed Dr Vojo Vukovic vice-president of clinical research. He will be the medical lead for the company's most advanced oncology product candidate, elesclomol. Dr Vukovic has more than 15 years' experience in oncology drug development and joins from Pfizer, where he was global medical lead for Sutent and axitinib in a number of cancer indications.
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.